Related Experiment Videos
The benzodiazepine receptor in normal and pathological human brain
The British Journal of Psychiatry : the Journal of Mental Science
|September 1, 1978
Summary
Benzodiazepine receptors in the brain are crucial for drug efficacy. Huntington's chorea reduces these receptors, potentially explaining why benzodiazepine treatments become less effective over time.
Area of Science:
- Neuroscience
- Pharmacology
- Neurochemistry
Background:
- Benzodiazepines are central nervous system drugs with high affinity for specific receptors.
- Benzodiazepine receptor binding correlates with drug potency and therapeutic effects.
- These receptors are primarily located in the brain's synaptic membranes, with high density in cortical areas.
Purpose of the Study:
- To investigate benzodiazepine receptor binding in the context of Huntington's chorea.
- To explore the relationship between receptor loss and therapeutic efficacy of benzodiazepines in this condition.
Main Methods:
- Analysis of benzodiazepine receptor binding in brain tissue samples.
- Comparison of receptor density in patients with Huntington's chorea versus control subjects.
- Localization of benzodiazepine receptors within specific neuronal populations.
Main Results:
- A significant decrease in benzodiazepine receptor binding was observed in the caudate nucleus and putamen of Huntington's chorea patients.
- This reduction in the putamen is attributed to a loss of receptors on GABAergic neurons, which degenerate in the disease.
- The loss of these receptors appears to correlate with the diminished therapeutic benefits of benzodiazepines in later disease stages.
Conclusions:
- Benzodiazepine receptor density is reduced in specific brain regions affected by Huntington's chorea.
- The degeneration of GABA neurons in Huntington's chorea leads to a loss of associated benzodiazepine receptors.
- This receptor loss may underlie the waning effectiveness of benzodiazepine therapies as Huntington's chorea progresses.